Benjamine Liu is the co-founder and CEO of TrialSpark, a technology company that is reimagining drug development. Benjamine received his DPhil at Oxford as a Rhodes Scholar, conducting his work with Sir Simon Lovestone. His doctoral thesis leveraged machine-learning, AI, and healthcare big-data -- genomics, proteomics, transcriptomics, metabolomics, imaging -- to develop diagnostics and therapeutics for Parkinson’s and Alzheimer’s disease. During his graduate work, he observed the way clinical trials bottlenecked the development of new treatments for patients, compelling him to start TrialSpark. TrialSpark's tech-forward clinical trial engine accelerates the drug development process. With an integrated data layer as its foundation, TrialSpark offers unprecedented study quality and speed through real-time access to data, process standardization, and operational agility. TrialSpark acquires majority or minority positions in drugs from other pharma companies/biotechs to run through its own trial engine, enabling these drugs to be tested far faster and more efficiently. Before TrialSpark, Ben graduated from Yale where he was awarded the college’s highest honor at graduation and received his MPhil with distinction in Computational Biology from the Department of Applied Mathematics and Theoretical Physics at Cambridge as a Paul Melon Fellow.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related